Arena Pharmaceuticals Inc (ARNA)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Amit D. Munshi
Employees:
194
6154 NANCY RIDGE DRIVE, SAN DIEGO, CA 92121
858-453-7200

Arena Pharmaceuticals, Inc. is a biopharmaceutical company engages in the discovery, development, and commercialization of novel drugs that target G protien-coupled receptors. It offers a range of drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in San Diego, CA.

Data derived from most recent annual or quarterly report
Market Cap 5.659 Billion Shares Outstanding61.074 Million Avg 30-day Volume 1.64 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-2.4
Price to Revenue2.9117 Debt to Equity0.0426 EBITDA483.502 Million
Price to Book Value2.1915 Operating Margin59.862 Enterprise Value1.283 Billion
Current Ratio16.9 EPS Growth13.206 Quick Ratio16.447
1 Yr BETA 0.6029 52-week High/Low 94.23 / 45.5 Profit Margin0.0
Operating Cash Flow Growth530.138 Altman Z-Score15.1917 Free Cash Flow to Firm 498.941 Million
View SEC Filings from ARNA instead.

View recent insider trading info

Funds Holding ARNA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ARNA BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

MUNSHI AMIT PRESIDENT AND CEO

  • Officer
  • Director
125,397 2022-01-03 5

STELZER LAURIE EVP & CHIEF FINANCIAL OFFICER

  • Officer
36,366 2022-01-03 3

AURENTZ VINCENT EXECUTIVE VP AND CBO

  • Officer
55,122 2022-01-03 3

LISICKI ROBERT EVP, CHIEF COMMERCIAL OFFICER

  • Officer
37,563 2022-01-03 4

SCHMIDT JOAN EVP, GENERAL COUNSEL & SEC

  • Officer
36,063 2022-01-03 3

MANION DOUGLAS J. EVP RESEARCH & DEVELOPMENT

  • Officer
36,462 2022-01-03 3

FETZER OLIVER

  • Director
16,894 2021-06-11 1

NOVA TINA SUSAN

  • Director
26,845 2021-06-11 1

GALLAHUE KIERAN

  • Director
20,113 2021-06-11 1

NEIL GARRY ARTHUR

  • Director
18,419 2021-06-11 1

DALLAS JAYSON DONALD ALEXANDER

  • Director
22,729 2021-06-11 2

JARRETT JENNIFER

  • Director
18,419 2021-06-11 1

KNOBIL KATHARINE

  • Director
14,023 2021-06-11 1

OUZREN NAWAL

  • Director
11,757 2021-06-11 3

SCHOCH STEVEN J

  • Director
15,403 2021-06-11 2

CABELL CHRISTOPHER EVP, HEAD OF R&D, AND CMO

  • Officer
1,401 2020-11-25 0

SONI MANMEET SINGH

  • Director
5,902 2020-06-17 0

KLASSEN PRESTON EVP AND CMO

  • Officer
0 2020-03-01 0

LIND KEVIN ROBERT EXECUTIVE VP AND CFO

  • Officer
0 2020-03-01 0

SPECTOR STEVEN W EVP, GENERAL COUNSEL & SEC

  • Officer
17,437 2020-02-27 0

WOODS RANDALL E

  • Director
14,230 2019-11-12 0

SCHNEIDER PHILLIP M

  • Director
0 2017-06-13 0

BICE SCOTT H

  • Director
0 2017-06-13 0

WHITE CHRISTINE ANNA

  • Director
0 2017-06-13 0

HIXSON HARRY F JR

  • Director
0 2016-06-13 0

BELCHER DONALD D

  • Director
0 2016-06-13 0

BEHAN DOMINIC P EVP & CHIEF SCIENTIFIC OFFICER

  • Officer
  • Director
0 2016-03-02 0

SHANAHAN WILLIAM R JR SVP & CHIEF MEDICAL OFFICER

  • Officer
0 2016-03-02 0

BIELASZ JENNIFER KATHLEEN VP, FINANCE AND ACCOUNTING

  • Officer
0 2016-03-02 0

AUDET CRAIG MICHAEL SVP, OPN & HEAD GLOB REG AFRS

  • Officer
0 2016-03-02 0

MEZZINO MAURICE JAMES SVP, CORPORATE DEVELOPMENT

  • Officer
0 2016-03-02 0

LIEF JACK PRESIDENT AND CEO

  • Officer
  • Director
622,189 2015-03-03 0

HOFFMAN ROBERT SVP, FINANCE AND CFO

  • Officer
58,074 2014-12-15 0

AJIT-SIMH K A SR. VP, QUALITY & REG COMPL

  • Officer
0 2011-03-15 0

LAFORCE JAMES

  • Director
0 2010-03-17 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

STELZER LAURIE - Officer EVP & CHIEF FINANCIAL OFFICER

2022-01-05 17:00:49 -0500 2022-01-03 A 21,462 a 36,366 direct 0.1935 -0.5699 1.1613 3 -0.5699 6

LISICKI ROBERT - Officer EVP, CHIEF COMMERCIAL OFFICER

2022-01-05 17:00:19 -0500 2022-01-03 A 21,462 a 37,563 direct 0.1935 -0.5699 1.1613 3 -0.5699 6

SCHMIDT JOAN - Officer EVP, GENERAL COUNSEL & SEC

2022-01-05 17:02:58 -0500 2022-01-03 A 21,462 a 36,063 direct 0.1935 -0.5699 1.1613 3 -0.5699 6

MANION DOUGLAS J. - Officer EVP RESEARCH & DEVELOPMENT

2022-01-05 17:02:25 -0500 2022-01-03 A 21,462 a 36,462 direct 0.1935 -0.5699 1.1613 3 -0.5699 6

AURENTZ VINCENT - Officer EXECUTIVE VP AND CBO

2022-01-05 16:59:48 -0500 2022-01-03 A 21,462 a 55,122 direct 0.1935 -0.5699 1.1613 3 -0.5699 6

MUNSHI AMIT - Director - Officer PRESIDENT AND CEO

2022-01-05 17:01:50 -0500 2022-01-03 A 85,847 a 125,397 direct 0.1935 -0.5699 1.1613 3 -0.5699 6

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
ARENA PHARMACEUTICALS INC ARNA 2022-01-14 22:15:03 UTC -0.18 0.25 1700000
ARENA PHARMACEUTICALS INC ARNA 2022-01-14 21:45:03 UTC -0.18 0.25 1700000
ARENA PHARMACEUTICALS INC ARNA 2022-01-14 21:15:03 UTC -0.18 0.25 1700000
ARENA PHARMACEUTICALS INC ARNA 2022-01-14 20:45:03 UTC -0.18 0.25 1700000
ARENA PHARMACEUTICALS INC ARNA 2022-01-14 20:15:03 UTC -0.18 0.25 1700000
ARENA PHARMACEUTICALS INC ARNA 2022-01-14 19:45:03 UTC -0.18 0.25 1700000
ARENA PHARMACEUTICALS INC ARNA 2022-01-14 19:15:04 UTC -0.18 0.25 1700000
ARENA PHARMACEUTICALS INC ARNA 2022-01-14 18:45:04 UTC -0.18 0.25 1700000
ARENA PHARMACEUTICALS INC ARNA 2022-01-14 18:15:03 UTC -0.18 0.25 1700000
ARENA PHARMACEUTICALS INC ARNA 2022-01-14 17:45:03 UTC -0.18 0.25 1700000
ARENA PHARMACEUTICALS INC ARNA 2022-01-14 17:15:03 UTC -0.18 0.25 1600000
ARENA PHARMACEUTICALS INC ARNA 2022-01-14 16:45:04 UTC -0.18 0.25 1600000
ARENA PHARMACEUTICALS INC ARNA 2022-01-14 16:15:03 UTC -0.18 0.25 1600000
ARENA PHARMACEUTICALS INC ARNA 2022-01-14 15:45:03 UTC -0.18 0.25 1600000
ARENA PHARMACEUTICALS INC ARNA 2022-01-14 15:15:03 UTC -0.18 0.25 1600000
ARENA PHARMACEUTICALS INC ARNA 2022-01-14 14:45:03 UTC -0.18 0.25 1600000
ARENA PHARMACEUTICALS INC ARNA 2022-01-14 14:15:03 UTC -0.18 0.25 1600000
ARENA PHARMACEUTICALS INC ARNA 2022-01-14 13:45:02 UTC -0.18 0.25 1600000
ARENA PHARMACEUTICALS INC ARNA 2022-01-14 13:15:03 UTC -0.18 0.25 1600000
ARENA PHARMACEUTICALS INC ARNA 2022-01-14 12:45:03 UTC -0.18 0.25 1400000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
Trust for Professional Managers- Convergence Market Neutral Fund ARNA -991.0 shares, $-69191.62 2020-08-31 N-PORT
FundVantage Trust- Gotham Defensive Long Fund ARNA -58.0 shares, $-2436.0 2020-03-31 N-PORT
FundVantage Trust- Gotham Index Plus All-Cap Fund ARNA -91.0 shares, $-3822.0 2020-03-31 N-PORT
RUSSELL INVESTMENT CO- U.S. Dynamic Equity Fund ARNA -1649.0 shares, $-122421.76 2021-01-31 N-PORT
Trust for Professional Managers- Convergence Long/Short Equity Fund ARNA -530.0 shares, $-28879.7 2021-11-30 N-PORT
ETF Series Solutions- The Acquirers Fund ARNA -6259.0 shares, $-359204.01 2021-10-31 N-PORT

Elevate your investments